LX2761

Overview

LX2761 is an orally active, dual SGLT1/SGLT2 inhibitor with IC 50 values of 2.2 nM and 2.7 nM against human SGLT1 and SGLT2 , respectively. LX2761 locks human SGLT1 in an outward-open conformation and blocks its putative water permeation pathway. After oral administration, LX2761 is confined exclusively to the intestinal lumen, delays intestinal glucose absorption, regulates intestinal glucose metabolism, increases cecal glucose levels, reduces cecal pH, improves glycemic control and elevates plasma total GLP-1 levels. However, LX2761 induces diarrhea in a dose-dependent manner. LX2761 can be used in diabetes-related research.

Application

Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Glucose Metabolism | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > SGLT | Products > Signaling Pathways > GLP Receptor

Product Information

• Catalog No.: HY-101122
• CAS No.: 1610954-97-6
• Molecular Formula: C32H47N3O6S
• Molecular Weight: 601.80
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.
• Availability: In-stock

Source

Original product source